Cadence Pharmaceuticals Reports Second Quarter 2007 Financi... (e initial Phase III clinical trial of Om...)

HOME >> BIOLOGY >> TECHNOLOGY

Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results

Date:8/19/2007

e initial Phase III clinical trial of Omigard. The company currently

anticipates completing enrollment of its new goal of 1,850 patients in

the second quarter of 2008 and, if the results are positive, submitting

a New Drug Application for Omigard in the first half of 2009.

-- Also in July 2007, Cadence signed a development and supply agreement

with Baxter Healthcare Corporation for the completion of

pre-commercialization manufacturing development activities and the

manufacture of commercial supplies of finished drug product for IV

acetaminophen.

-- In June 2007, the company completed enrollment of the original target

of 1,250 patients in the Omigard clinical trial two months ahead of

schedule.

Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time

Cadence management will host a conference call on Tuesday, August 14, 2007 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss financial results for the second quarter ended June 30, 2007. Interested investors may participate in the conference call by dialing (888) 802-2225 (domestic) or (913) 312-1268 (international). To access the webcast, please log on to the company's website at http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, intravenous acetaminophen for the treatment of acute pain and fever, and Omigard (omiganan pentahydrochloride
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.

0

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss

Post Your Comments:

Cadence Pharmaceuticals Reports Second Quarter 2007 Financi...(e initial Phase III clinical trial of Om...)